Bausch Health Companies Inc. (T:BHC*CA)

Business Focus: Pharmaceuticals (NEC)

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 2150 Saint-Elzear Blvd W
LAVAL QC H7L 4A8
Tel: 1-949-4616002
Website: https://www.bauschhealth.com
IR: See website
<
Key People
Thomas J. Appio
Chief Executive Officer, Director
John S. Barresi
Interim Chief Financial Officer
Seana-Lyn Carson
Executive Vice President, General Counsel
Business Overview
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Financial Overview
For the three months ended 31 March 2024, Bausch Health Companies Inc revenues increased 11% to $2.15B. Net loss decreased 68% to $64M. Revenues reflect Bausch & Lomb / International segment increase of 18% to $1.1B, International Rx segment increase of 7% to $265M, Solta medical segment increase of 21% to $88M, United States and Puerto Rico segment increase of 13% to $1.25B, Other Foreign Countries segment increase of 8% to $256M.
Employees: 20,270 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $33,256M as of Mar 31, 2024
Annual revenue (TTM): $12,269M as of Mar 31, 2024
EBITDA (TTM): $4,019M as of Mar 31, 2024
Net annual income (TTM): -$622.62M as of Mar 31, 2024
Free cash flow (TTM): $1,074M as of Mar 31, 2024
Net Debt Last Fiscal Year: $29,203M as of Mar 31, 2024
Shares outstanding: 366,674,264 as of Mar 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.